Market Cap 3.51M
Revenue (ttm) 4.60M
Net Income (ttm) -7.68M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -166.96%
Debt to Equity Ratio 0.00
Volume 63,909
Avg Vol 3,910,614
Day's Range N/A - N/A
Shares Out 1.21M
Stochastic %K 20%
Beta 0.30
Analysts Strong Buy
Price Target $45.00

Company Profile

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. It operates through two segments: InMed Pharma and BayMedica Commercial. The InMed Pharma segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products inc...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 604 669 7207
Fax: 778 945 6800
Address:
885 West Georgia Street, Suite 1445, Vancouver, Canada
Firedolphin21
Firedolphin21 Jul. 7 at 1:39 PM
$LGPS $WETO $INM $BMGL $OGEN Dbr Nobody in the market is better N o b o d y... The GOAT
0 · Reply
Bulltrader988
Bulltrader988 Jul. 4 at 7:20 PM
$INM who is this single investor? 👃👀
0 · Reply
lookout408
lookout408 Jul. 2 at 3:33 PM
$INM money money pls hold if you do come over pls
0 · Reply
Bulltrader988
Bulltrader988 Jun. 30 at 8:44 PM
$INM interesting 8k out.... "...single institutional accredited investor ..." 👃👀 "... Entry into a Material Definitive Agreement. On June 24, 2025, InMed Pharmaceuticals Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a single institutional accredited investor (the “Purchaser”), for the sale and issuance of an aggregate of 1,952,363 of its common shares (or pre-funded warrants in lieu thereof) at a purchase price of $2.561 per share (or pre-funded warrant in lieu thereof). In addition, the Company agreed to issue to the Purchaser short-term preferred investment options to purchase up to an aggregate of 1,952,363 common shares at an exercise price of $2.436 per share. The foregoing transaction is referred to herein as the “Private Placement..." https://www.sec.gov/ix?doc=/Archives/edgar/data/1728328/000121390025059673/ea0247476-8k_inmed.htm
0 · Reply
StockSenseiTrendTraders
StockSenseiTrendTraders Jun. 30 at 8:21 PM
🔥 Top Winning Alerts in June! 🔥 1️⃣ $BMNR 🚀 +624.74% 🔹 Entry: 5.78 🔹 High: 41.89 2️⃣ $CYN 🚀 +304.09% 🔹 Entry: 10.28 🔹 High: 41.54 3️⃣ $RBNE 🚀 +280.93% 🔹 Entry: 5.40 🔹 High: 20.57 4️⃣ $INM 🚀 +186.93% 🔹 Entry: 3.29 🔹 High: 9.44 5️⃣ $EVGN 🚀 +132.87% 🔹 Entry: 1.43 🔹 High: 3.33 📊 June Stats ✅ Wins: 130 ❌ Losses: 9 📊 2025 Performance Highlights ✅ Wins: 652 ❌ Losses: 44 🚀 Gain Potential: +29,845% ✨ Avg Gain/Winning Alert: 45.77%
0 · Reply
raul123
raul123 Jun. 30 at 3:27 PM
$INM Updates - high volatility stock: 2. Encouraging Preclinical Data for INM‑901 Date: June 24, 2025 In a Form 8-K under Regulation FD, InMed revealed that INM‑901 significantly reduced multiple neuroinflammation markers in ex‑vivo Alzheimer’s disease models finance.yahoo.com No clinical data yet, but this ex‑vivo result marks a notable early proof-of-concept for their Alzheimer’s pipeline . 📈 Market & Financial Context Stock Spike: INM stock surged ~70–200% on June 24 following the INM‑901 announcement, according to Stockstotrade inmedpharma.com Financial Position: Cash reserves of $3–5M are bolstered by the recent placement, though further capital raises may be needed to sustain R&D efforts stocktitan.net 👉Volatility: Classified as a micro-cap biotech with high beta (~3.3), INM is prone to sharp price swings from news catalysts .
0 · Reply
patatechaude
patatechaude Jun. 30 at 2:26 PM
$INM I took a small bite. I can see partnership or acquisition on Alzheimer…
0 · Reply
Kono6
Kono6 Jun. 30 at 1:36 AM
$CDT $INM News soon
0 · Reply
John62
John62 Jun. 30 at 12:28 AM
$CDT $INM Needs news for that kinda move but yes certainly possible
0 · Reply
simplifocused
simplifocused Jun. 29 at 7:38 PM
$CDT $INM I am optimistic NFA
0 · Reply
Latest News on INM
InMed Announces Results of 2024 Annual General Meeting

Dec 18, 2024, 8:00 PM EST - 7 months ago

InMed Announces Results of 2024 Annual General Meeting


InMed Enters Into Standby Equity Purchase Agreement

Dec 17, 2024, 4:56 PM EST - 7 months ago

InMed Enters Into Standby Equity Purchase Agreement


InMed to Present at the Emerging Growth Conference

Jun 10, 2024, 5:18 PM EDT - 1 year ago

InMed to Present at the Emerging Growth Conference


InMed Announces Results of 2023 Annual General Meeting

Dec 19, 2023, 6:03 PM EST - 1 year ago

InMed Announces Results of 2023 Annual General Meeting


InMed Provides Update on BayMedica Rare Cannabinoid Business

Jul 20, 2023, 7:30 AM EDT - 2 years ago

InMed Provides Update on BayMedica Rare Cannabinoid Business


Firedolphin21
Firedolphin21 Jul. 7 at 1:39 PM
$LGPS $WETO $INM $BMGL $OGEN Dbr Nobody in the market is better N o b o d y... The GOAT
0 · Reply
Bulltrader988
Bulltrader988 Jul. 4 at 7:20 PM
$INM who is this single investor? 👃👀
0 · Reply
lookout408
lookout408 Jul. 2 at 3:33 PM
$INM money money pls hold if you do come over pls
0 · Reply
Bulltrader988
Bulltrader988 Jun. 30 at 8:44 PM
$INM interesting 8k out.... "...single institutional accredited investor ..." 👃👀 "... Entry into a Material Definitive Agreement. On June 24, 2025, InMed Pharmaceuticals Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a single institutional accredited investor (the “Purchaser”), for the sale and issuance of an aggregate of 1,952,363 of its common shares (or pre-funded warrants in lieu thereof) at a purchase price of $2.561 per share (or pre-funded warrant in lieu thereof). In addition, the Company agreed to issue to the Purchaser short-term preferred investment options to purchase up to an aggregate of 1,952,363 common shares at an exercise price of $2.436 per share. The foregoing transaction is referred to herein as the “Private Placement..." https://www.sec.gov/ix?doc=/Archives/edgar/data/1728328/000121390025059673/ea0247476-8k_inmed.htm
0 · Reply
StockSenseiTrendTraders
StockSenseiTrendTraders Jun. 30 at 8:21 PM
🔥 Top Winning Alerts in June! 🔥 1️⃣ $BMNR 🚀 +624.74% 🔹 Entry: 5.78 🔹 High: 41.89 2️⃣ $CYN 🚀 +304.09% 🔹 Entry: 10.28 🔹 High: 41.54 3️⃣ $RBNE 🚀 +280.93% 🔹 Entry: 5.40 🔹 High: 20.57 4️⃣ $INM 🚀 +186.93% 🔹 Entry: 3.29 🔹 High: 9.44 5️⃣ $EVGN 🚀 +132.87% 🔹 Entry: 1.43 🔹 High: 3.33 📊 June Stats ✅ Wins: 130 ❌ Losses: 9 📊 2025 Performance Highlights ✅ Wins: 652 ❌ Losses: 44 🚀 Gain Potential: +29,845% ✨ Avg Gain/Winning Alert: 45.77%
0 · Reply
raul123
raul123 Jun. 30 at 3:27 PM
$INM Updates - high volatility stock: 2. Encouraging Preclinical Data for INM‑901 Date: June 24, 2025 In a Form 8-K under Regulation FD, InMed revealed that INM‑901 significantly reduced multiple neuroinflammation markers in ex‑vivo Alzheimer’s disease models finance.yahoo.com No clinical data yet, but this ex‑vivo result marks a notable early proof-of-concept for their Alzheimer’s pipeline . 📈 Market & Financial Context Stock Spike: INM stock surged ~70–200% on June 24 following the INM‑901 announcement, according to Stockstotrade inmedpharma.com Financial Position: Cash reserves of $3–5M are bolstered by the recent placement, though further capital raises may be needed to sustain R&D efforts stocktitan.net 👉Volatility: Classified as a micro-cap biotech with high beta (~3.3), INM is prone to sharp price swings from news catalysts .
0 · Reply
patatechaude
patatechaude Jun. 30 at 2:26 PM
$INM I took a small bite. I can see partnership or acquisition on Alzheimer…
0 · Reply
Kono6
Kono6 Jun. 30 at 1:36 AM
$CDT $INM News soon
0 · Reply
John62
John62 Jun. 30 at 12:28 AM
$CDT $INM Needs news for that kinda move but yes certainly possible
0 · Reply
simplifocused
simplifocused Jun. 29 at 7:38 PM
$CDT $INM I am optimistic NFA
0 · Reply
Bulltrader988
Bulltrader988 Jun. 29 at 7:13 PM
$INM last week was good and now lets fight further this week bulls 👃👀
0 · Reply
Kono6
Kono6 Jun. 29 at 6:15 PM
$CDT Feels like this one is going to pull an $INM. From the 2.00's to the 9.00's in premarket
0 · Reply
buythewinners
buythewinners Jun. 29 at 3:42 PM
$IXHL $INM $INMB $RMD $LLY $PFE TOP LINE phase2 results due in July for OSA pill form therapy! FDA approved Phase3 already which is going on in both the US & UK. DON'T MISS THIS ONE!! ROI
0 · Reply
davis8uni
davis8uni Jun. 28 at 12:10 AM
0 · Reply
Bulltrader988
Bulltrader988 Jun. 27 at 7:43 PM
$INM this week 👃👀
0 · Reply
patatechaude
patatechaude Jun. 27 at 7:22 PM
$INM It will go up, the borrow fees on this are insane. https://www.iborrowdesk.com/report/inm
0 · Reply
BigT263
BigT263 Jun. 27 at 6:31 PM
$INM trash
0 · Reply
Bulltrader988
Bulltrader988 Jun. 27 at 11:17 AM
$INM offering closed 👃👀 https://www.stocktitan.net/news/INM/in-med-pharmaceuticals-announces-closing-of-5-million-private-cd8ej2fqv15r.html
1 · Reply
newsfile_corp
newsfile_corp Jun. 27 at 11:00 AM
https://nfne.ws/257024 $INM @inmedpharma #cannabinoids #inm #inmed #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #Fin
0 · Reply
patatechaude
patatechaude Jun. 26 at 6:19 PM
$INM +$20M market cap is warranted IMO.
0 · Reply
patatechaude
patatechaude Jun. 26 at 5:24 PM
$INM Can this be bought for $20M?
0 · Reply
dbr_island
dbr_island Jun. 26 at 3:45 PM
$EKSO reminds me of $INM when I was pounding the table under $2 and ran to $9+ $CYN $VOR $GNS all paying 💰💰💰
0 · Reply